Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial. METHODS: Adults with active AS and inadequate response/intolerance to two or more NSAIDs were rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksymowych, Walter P, Østergaard, Mikkel, Landewé, Robert, Barchuk, William, Liu, Ke, Tasset, Chantal, Gilles, Leen, Hendrikx, Thijs, Besuyen, Robin, Baraliakos, Xenofon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071516/
https://www.ncbi.nlm.nih.gov/pubmed/34352069
http://dx.doi.org/10.1093/rheumatology/keab543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071516/
https://www.ncbi.nlm.nih.gov/pubmed/34352069
http://dx.doi.org/10.1093/rheumatology/keab543

Ejemplares similares